SCHEMBL78700

SCHEMBL78700

COC1CCCSC1OC1SCCCC1OC

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13601261 0.73
SCHEMBL1146008 0.70
SCHEMBL9197226 0.65
SCHEMBL21727237 0.65 KDM4E (0.46) KDM4E
SCHEMBL2904322 0.65 KDM4E (0.46) KDM4E
SCHEMBL5481927 0.65
SCHEMBL11501519 0.65 KDM4E (0.46) KDM4E
SCHEMBL15062108 0.65
SCHEMBL10268948 0.65 KDM4E (0.46) KDM4E
SCHEMBL772885 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873691-B2 TRPV1 antagonists including dihydroxy substituent and uses thereof PURDUE PHARMA L.P. (US) 2018-01-23 US disclosed
US-20160318920-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF PURDUE PHARMA L.P. 2016-11-03 US disclosed
US-9394293-B2 TRPV1 antagonists including dihydroxy substituent and uses thereof PURDUE PHARMA L.P. (US) 2016-07-19 US disclosed
US-9017726-B2 Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-04-28 US disclosed
EP-2855558-A2 POLYCARBONATE POLYOL COMPOSITIONS AND METHODS Novomer, Inc. (US) 2015-04-08 EP disclosed
US-20140350056-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF PURDUE PHARMA L.P. 2014-11-27 US disclosed
US-20140031289-A1 POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-01-30 US disclosed
WO-2013177546-A2 POLYCARBONATE POLYOL COMPOSITIONS AND METHODS NOVOMER, INC. (US) 2013-11-28 WO disclosed
WO-2013021276-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF PURDUE PHARMA L.P. (US) 2013-02-14 WO disclosed
US-20120121517-A1 BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF Korean Institute of Science and Technology of Seoul, Republic of Korea 2012-05-17 US disclosed
EP-1472225-A2 2-PIPERAZINE-PYRIDINES USEFUL FOR TREATING PAIN Euro-Celtique S.A. (LU) 2004-11-03 EP disclosed
WO-2004029031-A2 THERAPEUTIC PIPERAZINE COMPOUNDS EURO-CELTQUE, S.A. (LU) 2004-04-08 WO disclosed
US-20040044003-A1 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. 2004-03-04 US disclosed
WO-2004011441-A1 PYRIDAZINYLPIPERAZINE DERIVATIVES FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2004-02-05 WO disclosed
EP-1383505-A2 INOSINE COMPOUNDS AND THEIR USE FOR TREATING OR PREVENTING AN INFLAMATION OR A REPERFUSION DISEASE Inotek Pharmaceuticals Corporation (US) 2004-01-28 EP disclosed
US-20040006091-A1 Therapeutic agents useful for treating or preventing pain PURDUE PHARMA L.P. 2004-01-08 US disclosed
WO-2003074520-A1 THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN EURO-CELTIQUE, S.A. (LU) 2003-09-12 WO disclosed
WO-2003066595-A2 2 - PIPERAZINE - PYRIDINES USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2003-08-14 WO disclosed
US-20030040502-A1 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease INOTEK PHARMACEUTICALS CORPORATION 2003-02-27 US disclosed
WO-2002076400-A2 INOSINE COMPOUNDS AND THEIR USE FOR TREATING OR PREVENTING AN INFLAMATION OR A REPERFUSION DISEASE INOTEK PHARMACEUTICALS CORPORATION (US) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121517-A1 BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF PHOSPHO1, HSPA2, FEM1B KDM4E 2925/4885
US-20040006091-A1 Therapeutic agents useful for treating or preventing pain OPRK1, OPRL1, OPRD1 KDM4E 4612/4885
US-20030040502-A1 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease NOS2, NOS1, ARG2 KDM4E 4327/4885
US-20160318920-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF TRPV1, TRPV2, TRPA1 KDM4E 4235/4885
US-20140031289-A1 POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF PHOSPHO1, PLCB3, INPP5D KDM4E 1770/4885
US-20140350056-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF TRPV1, TRPV2, TRPA1 KDM4E 4235/4885
US-20040044003-A1 Therapeutic agents useful for treating pain GRIK5, HBS1L, GABRR1 KDM4E 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.